UBS Group’s Strategic Trust Kelly CRISPR & Gene Editing Technology ETF XDNA Stock Holding History

UBS Group’s Portfolio XDNA Stock Details XDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-419	Closed	-$3.11K	–	10388
2023 Q3	$3.11K	Buy	+419	New	+$3.61K	﹤0.01%	7609
2023 Q1	–	Sell	-5,352	Closed	-$53.2K	–	10970
2022 Q4	$53.2K	Sell	5,352 -166	-3%	-$1.86K	﹤0.01%	6719
2022 Q3	$65K	Buy	5,518 +5,367	+3,554%	+$67.9K	﹤0.01%	6097
2022 Q2	$2K	Buy	+151	New	+$1.57K	﹤0.01%	9686

UBS Group's XDNA Position: Q4 2023 in Review

UBS Group sold out of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) in Q4 2023, closing a stake of 419 shares — an estimated $3.11K sold.

UBS Group first reported a position in XDNA in Q2 2022 and held it in 4 quarters. The position peaked at $65K in Q3 2022. 0 funds tracked by Wall St. Rank hold XDNA as of Q4 2023.

UBS Group reported no remaining Strategic Trust Kelly CRISPR & Gene Editing Technology ETF position as of Q4 2023 after selling out during the quarter.
UBS Group sold 419 Strategic Trust Kelly CRISPR & Gene Editing Technology ETF shares in Q4 2023, an estimated $3.11K.
UBS Group first reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in Q2 2022 and held it in 4 quarters.
UBS Group's Strategic Trust Kelly CRISPR & Gene Editing Technology ETF position peaked at $65K in Q3 2022.
0 funds tracked by Wall St. Rank held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.